Clinical Trials: Page 53


  • This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
    Image attribution tooltip

    India clears a psoriasis drug for COVID-19, and a tiny US biotech's shares soar

    An emergency approval for Biocon's drug Alzumab in India could lead its U.S. partner, Equillium, to start broader trials in coronavirus disease.

    By July 13, 2020
  • Image attribution tooltip
    GlaxoSmithKline
    Image attribution tooltip

    FDA documents reveal doubts about GSK blood cancer drug

    Eye-related side effects could derail the leading drug that homes in on a new multiple myeloma target, just as rival therapies progress toward FDA review.

    By July 10, 2020
  • Trendline

    Oncology's research boom

    More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

    By BioPharma Dive staff
  • This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from https://www.flickr.com/photos/nihgov/49565662436/in/album-72157713108522106/.
    Image attribution tooltip

    In the UK, a coronavirus study shows how to get fast, powerful data during a pandemic

    RECOVERY, a large trial of COVID-19 treatments in the U.K., produced much of what the world knows about which medicines work and which do not. 

    By Ned Pagliarulo • July 10, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip
    ALS drug development

    In the hunt for ALS treatments, researchers find promise in silencing genes

    Two studies published in the New England Journal of Medicine, including one that tested a Biogen drug, provide some evidence that a decades-long effort to develop genetic medicines for ALS is starting to pay off.

    By July 8, 2020
  • Novavax COVID-19 candidate vaccine NVX-CoV2373 administered to first patients in Phase I Clinical Trial
    Image attribution tooltip
    Courtesy of Novavax, Australian Broadcasting Corporation
    Image attribution tooltip

    Novavax gets $1.6B in US funding for coronavirus vaccine

    The funding will secure 100 million doses of Novavax's experimental shot, which is set to begin late-stage testing this fall.

    By Ned Pagliarulo • July 7, 2020
  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    Regeneron advances COVID-19 antibody cocktail into late-stage trials

    The launch of a Phase 3 prevention study accelerates work on antibody-based drugs, which could offer strained healthcare systems a "bridge" to a vaccine.

    By July 6, 2020
  • Image attribution tooltip
    Permission granted by PRA Health Sciences
    Image attribution tooltip
    Sponsored by PRA Health Sciences

    Collaboration, not competition, will bring better pediatric medicines to market

    Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. 

    July 6, 2020
  • A vial of BNT162, an experimental coronavirus vaccine being developed by BioNTech and Pfizer
    Image attribution tooltip
    Permission granted by BioNTech SE
    Image attribution tooltip

    Coronavirus vaccine from Pfizer, BioNTech shows early potential

    Initial data from a small study of healthy volunteers show the companies' shot can elicit immune responses against the virus.

    By Ned Pagliarulo • July 1, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA insists it 'will not cut corners' in coronavirus vaccine approvals

    New guidelines released by the agency detail what reviewers will require from drugmakers before approving or making available any coronavirus vaccine. 

    By Ned Pagliarulo • June 30, 2020
  • Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient.
    Image attribution tooltip
    National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
    Image attribution tooltip

    Without data, Inovio says study shows positive results for coronavirus vaccine

    The biotech is among the first few companies to disclose preliminary trial results for a coronavirus shot. But Inovio shared few details, making its announcement difficult to assess.

    By June 30, 2020
  • Electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
    Image attribution tooltip

    Large UK study finds no benefit to HIV antiviral in COVID-19

    The results are the third significant clinical finding from the RECOVERY study, which recently determined the steroid dexamethasone improved survival.

    By Ned Pagliarulo • June 30, 2020
  • A piece of DNA stretches vertically along a plain background.
    Image attribution tooltip
    Getty / Edited by BioPharma Dive
    Image attribution tooltip

    Third patient dies in halted study of Audentes gene therapy

    The three patients, treated for a rare neuromuscular disease, were given a high dose of Audentes' gene therapy.

    By Updated Aug. 21, 2020
  • A volunteer in a clinical trial is dosed with BNT162, an experimental coronavirus vaccine developed by Pfizer and BioNTech
    Image attribution tooltip
    Permission granted by BioNTech SE
    Image attribution tooltip

    WHO lays out ambitious plan to deliver 2 billion coronavirus vaccine doses

    More than $18 billion will be needed for the WHO's plan, which would secure and allocate vaccine supplies for high-risk groups and lower-income countries.

    By Ned Pagliarulo • June 26, 2020
  • Image attribution tooltip

    Shutterstock.com/Maurice Lesca

    Image attribution tooltip
    Sponsored by PSI CRO

    Clinical trials are only getting more complex, and wishful thinking has to go

    If you look at the data trends over the last decade, there's no avoiding the truth: clinical trials are getting more complex every year.

    By Natania Barron Global Director, Marketing • June 26, 2020
  • House Energy and Commerce hearing on COVID-19 June 23 2020
    Image attribution tooltip

    Screenshot of House E&C hearing, June 23, 2020

    Image attribution tooltip

    Fauci 'cautiously optimistic' about coronavirus vaccine by 2021

    Anthony Fauci, the nation's top infectious disease official, told lawmakers the next few weeks will be critical as COVID-19 cases rise in many states.

    By Rebecca Pifer Parduhn • June 24, 2020
  • A transmission electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
    Image attribution tooltip

    NIH ends key COVID-19 studies of hydroxychloroquine

    The agency stopped one trial because the malaria drug didn't appear to be helping patients, and halted the second because few people were enrolling.

    By June 22, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck gives 1st look at Phase 3 results for its Prevnar competitor

    Results from two late-stage studies of V114, Merck's experimental pneumococcal conjugate vaccine, could help support a submission for approval later this year.

    By Ned Pagliarulo • June 22, 2020
  • UniQure gets out the gate first in race for Huntington's gene therapy

    The biotech has dosed patients in the first trial of a gene-targeted treatment for the degenerative disease, but competitor Voyager could be chasing soon.

    By June 19, 2020
  • A transmission electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
    Image attribution tooltip

    Chinese biotech to test GSK, Dynavax adjuvants in coronavirus vaccine study

    A Phase 1 study of Clover Biopharmaceuticals' experimental vaccine will also test technologies used to boost the body's immune response to inoculation.

    By Ned Pagliarulo • June 19, 2020
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    In big year for microbiome drugs, a small biotech sets the bar

    Data from Finch Therapeutics will likely be held up against two rivals planning to present their own clinical results later this year. 

    By June 19, 2020
  • An electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158853/.
    Image attribution tooltip

    Cheap steroid lowers risk of death in hospitalized COVID-19 patients, U.K. study finds

    The results from the RECOVERY trial were one of the few bright spots over the summer, when vaccines were still in testing and doctors the world over were desperate for effective treatments.

    By June 16, 2020
  • A building with logo of drugmaker Eli Lilly.
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip

    Lilly claims success in early breast cancer study, leaping past Pfizer

    The results for Lilly's Verzenio come just weeks after Pfizer's drug Ibrance fell short in a similar trial, and sent shares in the Indianapolis drugmaker soaring.

    By June 16, 2020
  • Image attribution tooltip

    iStock.com/vejaa

    Image attribution tooltip
    Sponsored by PRA Health Sciences

    Informing parents and protecting children as they navigate pediatric trials

    As the RACE Act prompts the need for more pediatric research, parents will need adequate time to ask questions, stay informed and ensure that their child is protected in a clinical trial.

    June 16, 2020
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive
    Image attribution tooltip

    Magenta's technology attracts another gene therapy developer

    A freshly inked research pact will test one of biotech's antibody drug conjugates as a conditioning treatment for patients receiving Beam Therapeutics' gene editing therapies.

    By June 15, 2020
  • Sinovac claims progress with early coronavirus vaccine study

    The Chinese drugmaker said trial results showed its vaccine spurred immune responses, with no serious side effects, but offered little data to support the claim.

    By Ned Pagliarulo • June 15, 2020